Infect Chemother.  2019 Sep;51(3):274-283. 10.3947/ic.2019.51.3.274.

Clinical Characteristics and Outcomes of Patients with Culture-Negative Pyogenic Spondylitis according to Empiric Glycopeptide Use

• Lee YD
• Jeon YH
• Kim YH
• Ha KY
• Hur JW
• Ryu KS
• Kim JS
• Kim YJ

• KMID: 2459043
• DOI: http://doi.org/10.3947/ic.2019.51.3.274

Abstract

BACKGROUND
The optimal choice of antibiotics is challenging in culture-negative pyogenic spondylitis (PS). The empiric use of glycopeptides is suggested depending on various risk factors, although clinical data are sparse. This study aimed to analyze the clinical characteristics and outcomes of patients with culture-negative PS and evaluate the effect of empiric glycopeptide use on clinical outcomes in these patients.
MATERIALS AND METHODS
Data on the characteristics, treatment, and outcomes of 175 patients diagnosed with PS were retrospectively obtained from the electronic database of a tertiary referral hospital from 2009 to 2016. Patients with negative culture results were grouped by the duration of glycopeptide treatment: glycopeptide therapy <28 days (Group A) and glycopeptide therapy ≥28 days (Group B).
RESULTS
Of 89 patients with negative culture results, 78 were included in the analysis (Group A, n = 66; Group B, n = 12). The mean age of patients with negative culture results was 65.5 years, and 52.6% were male. The median follow-up duration was 573 (interquartile range [IQR], 83 - 1,037) days. The duration of intravenous glycopeptide therapy was 0.0 (IQR, 0.0 - 0.0) days and 55.5 (IQR, 37.0 - 75.7) days for Groups A and B, respectively. Patients who used glycopeptide longer empirically (Group B) had more commonly undergone a previous spinal procedure, including surgery (P = 0.024). The length of hospitalization, erythrocyte sedimentation rate, and C-reactive protein level were significantly higher in Group B compared with those in Group A (P <0.001, P <0.001, and P = 0.006, respectively). Regarding treatment modalities, patients in Group B underwent surgery more frequently (P = 0.017). The duration of parenteral antibiotic treatment was longer in Group B (P <0.001). Recurrence was noted in 7 patients (9.0%), and the recurrence rate was not significantly different between the 2 groups (Group A, 5/66 [7.6%]; Group B, 2/12 [16.7%]; P = 0.293).
CONCLUSION
The recurrence rate among patients with culture-negative PS was not different based on the duration of empiric glycopeptide use. However, considering the small sample size and heterogeneity of our study population, we suggest that it is reasonable to administer glycopeptide antibiotics in these patients depending on clinical risk factors. Further large-scale prospective studies are needed to obtain more evidence for appropriate antibiotic treatment.

Keyword

Antibiotics; Culture; Glycopeptide; Pyogenic spondylodiscitis

MeSH Terms

Anti-Bacterial Agents
Blood Sedimentation
C-Reactive Protein
Follow-Up Studies
Glycopeptides
Hospitalization
Humans
Male
Population Characteristics
Prospective Studies
Recurrence
Retrospective Studies
Risk Factors
Sample Size
Spondylitis*
Tertiary Care Centers
Anti-Bacterial Agents
C-Reactive Protein
Glycopeptides

Figure

• 

  Figure 1 Study flow chart.

Reference

1. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010; 65:Suppl 3. iii11–iii24.

2. Boody BS, Jenkins TJ, Maslak J, Hsu WK, Patel AA. Vertebral osteomyelitis and spinal epidural abscess: an evidence-based review. J Spinal Disord Tech. 2015; 28:E316–E327.

3. Nickerson EK, Sinha R. Vertebral osteomyelitis in adults: an update. Br Med Bull. 2016; 117:121–138.

4. Korean Society for Chemotherapy. Korean Society of Infectious Diseases. Korean Orthopaedic Association. Clinical guidelines for the antimicrobial treatment of bone and joint infections in Korea. Infect Chemother. 2014; 46:125–138.

5. Park KH, Chong YP, Kim SH, Lee SO, Choi SH, Lee MS, Jeong JY, Woo JH, Kim YS. Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus . J Infect. 2013; 67:556–564.

6. Agency for Healthcare Research and Quality. Statistical brief #35: Infections with methicillin-resistant Staphylococcus aureus (MRSA) in U.S. hospitals, 1993–2005. Accessed 4 September 2019. Available at: http://hcup-us.ahrq.gov/reports/statbriefs/sb35.jsp.

7. Bhagat S, Mathieson C, Jandhyala R, Johnston R. Spondylodiscitis (disc space infection) associated with negative microbiological tests: comparison of outcome of suspected disc space infections to documented non-tuberculous pyogenic discitis. Br J Neurosurg. 2007; 21:473–477.

8. Lora-Tamayo J, Euba G, Narváez JA, Murillo O, Verdaguer R, Sobrino B, Narváez J, Nolla JM, Ariza J. Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum. 2011; 41:247–255.

9. Kim J, Kim YS, Peck KR, Kim ES, Cho SY, Ha YE, Kang CI, Chung DR, Song JH. Outcome of culture-negative pyogenic vertebral osteomyelitis: comparison with microbiologically confirmed pyogenic vertebral osteomyelitis. Semin Arthritis Rheum. 2014; 44:246–252.

10. Kehrer M, Pedersen C, Jensen TG, Lassen AT. Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect. 2014; 68:313–320.

11. Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I, Villanueva C, Pahissa A. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med. 2005; 118:1287.

12. Mustapić M, Višković K, Borić I, Marjan D, Zadravec D, Begovac J. Vertebral osteomyelitis in adult patients-characteristics and outcome. Acta Clin Croat. 2016; 55:9–15.

13. Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD, Huddleston PM III, Petermann GW, Osmon DR. Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015; 61:e26–e46.

14. Hopkinson N, Stevenson J, Benjamin S. A case ascertainment study of septic discitis: clinical, microbiological and radiological features. QJM. 2001; 94:465–470.

15. Yoon SH, Chung SK, Kim KJ, Kim HJ, Jin YJ, Kim HB. Pyogenic vertebral osteomyelitis: identification of microorganism and laboratory markers used to predict clinical outcome. Eur Spine J. 2010; 19:575–582.

16. Viale P, Furlanut M, Scudeller L, Pavan F, Negri C, Crapis M, Zamparini E, Zuiani C, Cristini F, Pea F. Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. Int J Antimicrob Agents. 2009; 33:379–382.

17. Luzzati R, Giacomazzi D, Danzi MC, Tacconi L, Concia E, Vento S. Diagnosis, management and outcome of clinically- suspected spinal infection. J Infect. 2009; 58:259–265.

18. Zimmerli W. Clinical practice. Vertebral osteomyelitis. N Engl J Med. 2010; 362:1022–1029.

19. Parikh MS, Antony S. A comprehensive review of the diagnosis and management of prosthetic joint infections in the absence of positive cultures. J Infect Public Health. 2016; 9:545–556.